Verastem Files Surprise $50M IPO for Cancer Stem Cell Work
Year-old start-up Verastem Inc. raised eyebrows Thursday when it said it filed for an initial public offering (IPO) to raise $50 million, a bold move for the Cambridge, Mass.-based biotech given that it's at least a year away from entering the clinic with its first cancer stem cell-targeting compound.
A decade ago, no one in the sector would have batted an eye at a preclinical-stage IPO.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter